Literature DB >> 3255919

Myasthenia gravis and Schmidt syndrome.

J K McAlpine1, J E Thomson.   

Abstract

We describe a 47 year old woman with a 30-year history of generalized myasthenia gravis whose condition had been stable and well controlled on a combination of pyridostigmine and ephedrine until she presented. At this time she gave a 2 month history of weakness, nausea, vomiting and more recently intermittent confusion. Investigations confirmed both primary hypothyroidism and primary adrenal failure (Schmidt syndrome). The autoimmune aetiology of these three conditions was confirmed by positive acetylcholine receptor, adrenal and thyroid microsomal antibodies.

Entities:  

Mesh:

Year:  1988        PMID: 3255919      PMCID: PMC2429035          DOI: 10.1136/pgmj.64.756.787

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  3 in total

1.  Immune disease and HLA associations with myasthenia gravis.

Authors:  P O Behan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

2.  Significance of thyrotropin excess in untreated primary adrenal insufficiency.

Authors:  D J Topliss; E L White; J R Stockigt
Journal:  J Clin Endocrinol Metab       Date:  1980-01       Impact factor: 5.958

3.  Myasthenia gravis and Schmidt syndrome.

Authors:  E P Bosch; P E Reith; D K Granner
Journal:  Neurology       Date:  1977-12       Impact factor: 9.910

  3 in total
  3 in total

Review 1.  Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes.

Authors:  Charlotte Vrinten; Angeli M van der Zwaag; Stephanie S Weinreich; Rob J P M Scholten; Jan J G M Verschuuren
Journal:  Cochrane Database Syst Rev       Date:  2014-12-17

Review 2.  Severe hyponatremia and Schmidt's syndrome.

Authors:  Edgard Wehbe; Michael E Grant
Journal:  Clin Exp Nephrol       Date:  2008-02-20       Impact factor: 2.801

3.  Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials.

Authors:  Charlotte Vrinten; Alexander F Lipka; Erik W van Zwet; Kirsten J M Schimmel; Martina C Cornel; Marja R Kuijpers; Yechiel A Hekster; Stephanie S Weinreich; Jan J G M Verschuuren
Journal:  BMJ Open       Date:  2015-07-16       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.